Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CUR101
- Development stage
- Preclinical
- Lead developer
- Curamys
- Modality
- RNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
CUR101 is a preclinical-stage microRNA (miRNA) therapeutic candidate being developed by Curamys for the treatment of Duchenne Muscular Dystrophy (DMD). The drug is designed to target specific disease-associated microRNAs that are implicated in the pathogenesis and progression of DMD. By modulating the levels of these miRNAs, CUR101 aims to regulate gene expression pathways involved in muscle degeneration, inflammation, and fibrosis, potentially slowing or halting the progression of the disease. The program is part of Curamys's broader pipeline utilizing miRNA-based modalities to address neuromuscular and neurodegenerative conditions.
- Other names
- CUR101CUR-101CUR 101
02
Targets
miR-21 (MicroRNA-21)
Beyond the preview
Go deeper on CUR101.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CUR101.